Kodiak Sciences (MEX:KOD) 9-Day RSI: 100.00 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:KOD Kodiak Sciences Inc MEX:KOD
27 GF Score
Price MXN749.00
! 4 Warning Signs
View Full Analysis

What is Kodiak Sciences 9-Day RSI?

Kodiak Sciences MEX:KOD 27 9-Day RSI is 100.00 as of Jul. 14, 2026. GuruFocus rates MEX:KOD with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 1,422 Biotechnology companies, Kodiak Sciences ranks worse than 90.65% on this metric.

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2026-07-14), Kodiak Sciences's 9-Day RSI is 100.00.

The industry rank for Kodiak Sciences's 9-Day RSI or its related term are showing as below:

MEX:KOD's 9-Day RSI is ranked worse than
90.65% of 1422 companies
in the Biotechnology industry
Industry Median: 47.095 vs MEX:KOD: 100.00

Kodiak Sciences  (MEX:KOD) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Kodiak Sciences 9-Day RSI Related Terms


MEX:KOD vs ABCL, AGIO, IMNM: 9-Day RSI Comparison

For the Biotechnology subindustry, Kodiak Sciences's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kodiak Sciences 9-Day RSI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kodiak Sciences's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Kodiak Sciences's 9-Day RSI falls into.


MEX:KOD
27GF Score
Kodiak Sciences Inc MEX:KOD
9-Day RSI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kodiak Sciences  (MEX:KOD) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 9-Day RSI →
What does a 9-Day RSI of 100.00 mean?
Kodiak Sciences (MEX:KOD) has a 9-Day RSI of 100.00 as of Jul. 14, 2026. According to the industry distribution chart, Kodiak Sciences ranks #1289 out of 1422 companies in the Biotechnology industry, placing it in the top 90.6%.
Is Kodiak Sciences' 9-Day RSI too high?
Kodiak Sciences' current 9-Day RSI is 100.00. The Biotechnology industry median 9-Day RSI is 47.10. Kodiak Sciences' value of 100.00 is 112.3% above this industry median. Based on the distribution chart, Kodiak Sciences ranks #1289 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kodiak Sciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Kodiak Sciences' 9-Day RSI compare to ABCL and AGIO?
According to the Biotechnology industry distribution chart, Kodiak Sciences ranks #1289 out of 1422 companies for 9-Day RSI. This places Kodiak Sciences in the lower half of its industry. The industry median 9-Day RSI is 47.10. Kodiak Sciences' value of 100.00 is 112.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 47.10, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kodiak Sciences's current 9-Day RSI of 100.00 is 112.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 47.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kodiak Sciences's current 9-Day RSI is 100.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kodiak Sciences stock overvalued right now?
Kodiak Sciences (MEX:KOD) has a current 9-Day RSI of 100.00. The current 9-Day RSI is 100.00 and 112.3% above the Biotechnology industry median of 47.10. Kodiak Sciences' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Kodiak Sciences (MEX:KOD), the current 9-Day RSI is 100.00 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kodiak Sciences Business Description

Other Exchanges KOD:USAK27:Germany
Address 1250 Page Mill Road, Palo Alto, CA, USA, 94304
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
27GF Score

Get the complete analysis for MEX:KOD

9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN749.00
Price